NAV-242
Inflammatory/Autoimmune Diseases
Phase 1Active
Key Facts
About Navigator Medicines
Navigator Medicines is advancing a novel pipeline of bispecific antibodies anchored in OX40L inhibition, with its lead candidate, NAV-240, having completed a Phase 1b trial and advancing into Phase 2a studies. The company's approach of dual inhibition of OX40L and TNFα is designed to achieve synergistic, targeted, and durable immune modulation for inflammatory disorders. Backed by a seasoned leadership team and premier life science investors like Forbion and RA Capital, Navigator is positioned to potentially redefine treatment paradigms in autoimmunity. Its strategy focuses on rapidly progressing its clinical assets to address significant unmet needs in dermatology and other inflammatory conditions.
View full company profileTherapeutic Areas
Other Inflammatory/Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| BionicMimics™ Platform | Scinai Immunotherapeutics | Discovery |
| Undisclosed Immunometabolism Program(s) | Inapill | Preclinical |
| A2AR PAM | Adoram Therapeutics | Hit-to-Lead |
| CAN10 | Cantargia | Phase I (Completed) |
| CAN14 | Cantargia | Preclinical |